- Quarter end
- 31 Dec 2025
- the date the book describes
- Filed
- 27 Oct 2026
- latest of these filings; the earliest 10 Feb 2026
- Managers listing it
- 25
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q3 2025 and Q4 2025; 10 listed it in both
- Shares listed
- 182,107,753
- combined, among listed positions
- Reported value
- $8.9bn
- combined, at the quarter end
Among the 92 comparable managers: 15 buyers (opened or added shares) and 13 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +6,892,452.
Managers listing GSK in Q4 2025
25 of 25 holders
Largest increases and reductions, by shares
Increases
- Wellington Management Group LLPexisting position · 12,557,487 shares now+9,137,167
- Acadian Asset Management LLCexisting position · 8,964,159 shares now+6,175,701
- Arrowstreet Capital LPnew position · 2,265,186 shares now+2,265,186
- Point72 Asset Management LPnew position · 1,474,951 shares now+1,474,951
- Fidelity (FMR LLC)existing position · 67,469,409 shares now+1,325,909
Reductions
- Dodge & Coxexisting position · 68,517,969 shares now-9,885,765
- Balyasny Asset Management LLCexisting position · 15,963 shares now-1,348,796
- Renaissance Technologies LLCexisting position · 1,035,572 shares now-952,381
- Jane Street Group LLCexisting position · 1,073,355 shares now-555,568
- Schonfeld Strategic Advisors LLCexisting position · 107,251 shares now-242,667
New positions and exits
New (5)
Exited (3)
- Capital Research Global Investorswas $77m
- Hudson Bay Capital Management LPwas $4.4m
- ExodusPoint Capital Management LPwas $850k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2022 | 1 | $19m | n.a. | n.a. |
| Q3 2022 | 18 | $3.9bn | n.a. | n.a. |
| Q4 2022 | 18 | $4.9bn | n.a. | n.a. |
| Q1 2023 | 13 | $4.4bn | n.a. | n.a. |
| Q2 2023 | 13 | $4.3bn | n.a. | n.a. |
| Q3 2023 | 16 | $4.5bn | n.a. | n.a. |
| Q4 2023 | 13 | $4.5bn | 6 | 7 |
| Q1 2024 | 13 | $5.3bn | 5 | 7 |
| Q2 2024 | 10 | $4.6bn | 6 | 4 |
| Q3 2024 | 10 | $4.9bn | 6 | 3 |
| Q4 2024 | 13 | $4.9bn | 11 | 2 |
| Q1 2025 | 11 | $6.3bn | 7 | 6 |
| Q2 2025 | 10 | $6.2bn | 8 | 3 |
| Q3 2025 | 11 | $7.5bn | 6 | 5 |
| Q4 2025 | 11 | $8.8bn | 15 | 13 |
| Q1 2026 | 9 | $9.1bn | 9 | 19 |
| Q2 2026 | 11 | $7.5bn | 15 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
GSK and LLY →GSK and JNJ →GSK and VRTX →Choose a stock to compare with GSK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own GSK, latest filings →Back to the 13F Explorer →